Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
http://www.tandfonline.com/doi/pdf/10.1586/era.12.81
Reference35 articles.
1. Renal-Cell Carcinoma
2. Estimates of the cancer incidence and mortality in Europe in 2006
3. Renal-Cell Carcinoma
4. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
5. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors;European Urology Focus;2022-11
2. Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The “retry” study from the Italian Group of Onco-Nephrology (G.I.O.N.);Journal of Onco-Nephrology;2022-05-04
3. Micro-RNA378a-3p Induces Apoptosis in Sarcomatoid Renal Cell Carcinoma and Regulates POLR2A and RUNX2 Expression;Anticancer Research;2022-01-29
4. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects;Biochemical and Biophysical Research Communications;2022-01
5. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model;Physiological Reports;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3